Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Decoding Hydrochlorothiazide/Lisinopril: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
1 October 2023
This article summarized the latest R&D progress of Hydrochlorothiazide/Lisinopril, the Mechanism of Action for Hydrochlorothiazide/Lisinopril, and the drug target R&D trends for Hydrochlorothiazide/Lisinopril.
Valuable Targets
6 min read
Potential Therapeutic Drug for Autoimmune and Neurodegenerative Diseases - RIPK1 Inhibitors
1 October 2023
RIPK1, also known as Receptor-interacting serine/threonine-protein kinase 1, is a multi-domain protein that includes an N-terminal kinase domain, intermediate domain, and a C-terminal death domain.
Drug Insights
4 min read
Deep Scientific Insights on Isophane Insulin's R&D Progress, Mechanism of Action, and Drug Target
1 October 2023
This article summarized the latest R&D progress of Isophane Insulin, the Mechanism of Action for Isophane Insulin, and the drug target R&D trends for Isophane Insulin.
Latest Hotspot
3 min read
NMD Pharma has launched a second-phase clinical trial for NMD670 in the treatment of Spinal Muscular Atrophyc
1 October 2023
NMD Pharma A/S has revealed that the initial patient has received their first dose in a Phase II clinical study of the ClC-1 inhibitor NMD670 in individuals affected by spinal muscular atrophy.
Drug Insights
4 min read
An In-depth Analysis of Magnesium Salicylate's R&D Progress and Mechanism of Action on Drug Target
1 October 2023
This article summarized the latest R&D progress of Magnesium Salicylate, the Mechanism of Action for Magnesium Salicylate, and the drug target R&D trends for Magnesium Salicylate.
Valuable Targets
6 min read
Analysis on the Clinical Research Progress of RAS antagonists
1 October 2023
The Renin-Angiotensin System (RAS) is a crucial fluid-regulating system composed of a series of peptide hormones and corresponding enzymes.
Drug Insights
4 min read
Miglitol: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
1 October 2023
This article summarized the latest R&D progress of Miglitol, the Mechanism of Action for Miglitol, and the drug target R&D trends for Miglitol.
Latest Hotspot
3 min read
Sandoz's Tyruko® (natalizumab), a unique biosimilar for multiple sclerosis, has been approved by the European Commission
1 October 2023
Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.
Drug Insights
4 min read
Nalidixic Acid Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
1 October 2023
This article summarized the latest R&D progress of Nalidixic Acid, the Mechanism of Action for Nalidixic Acid, and the drug target R&D trends for Nalidixic Acid.
Valuable Targets
5 min read
Potent "bone-protecting drugs" - RANKL inhibitors
1 October 2023
RANKL, or Receptor Activator of Nuclear Factor Kappa-B Ligand, is a crucial protein involved in the regulation of bone metabolism in the human body.
Drug Insights
4 min read
Unleashing the Power of Naphazoline Hydrochloride: A Comprehensive Review on R&D Breakthroughs
1 October 2023
This article summarized the latest R&D progress of Naphazoline Hydrochloride, the Mechanism of Action for Naphazoline Hydrochloride, and the drug target R&D trends for Naphazoline Hydrochloride.
Latest Hotspot
3 min read
Lantern Pharma reports initial patient treated in the Phase 1 trial of LP-184 for Advanced Solid Malignancies
1 October 2023
Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.